Quick Answer: China makes 6 major medical robot brands at $80K–$600K — including MicroPort Toumai ($400K–$600K, NMPA-approved laparoscopic surgery), TINAVI TiRobot ($350K–$500K, 20,000+ orthopedic cases), Fourier ExoMotus M4 ($80K–$150K, deployed in 2,000+ rehab centers), Remebot neurosurgical ($250K–$400K), and Siasun pharmacy automation ($120K–$250K). All have NMPA approval (China's FDA-equivalent); most have CE marks. Compared to Intuitive Surgical's da Vinci ($1.5M–$2.5M) and ReWalk ($85K+), Chinese systems deliver 30–75% cost savings with comparable clinical performance.
China's medical robotics industry has matured rapidly. Domestic systems are receiving regulatory approval and gaining clinical adoption in hospitals worldwide — from surgical robots competing with Intuitive Surgical's da Vinci, to rehabilitation exoskeletons deployed in thousands of centers across Asia, Europe, and Latin America.
This guide covers all three categories — surgical, rehabilitation, and pharmacy automation — with verified prices from manufacturers, NMPA / CE approval status, and a step-by-step import path for buyers outside China.
Surgical Robots
Surgical robots assist surgeons with precision, stability, and minimally invasive access. China's leading surgical robot platforms are now competing with US/EU incumbents on both capability and price.
TiRobot — Orthopedic Surgery
Developed by Tinavi Medical Technologies (Beijing), TiRobot is China's most clinically validated surgical robot. It assists in spinal and orthopedic procedures with sub-millimeter accuracy, reducing radiation exposure for both patient and surgeon.
- Price: $350,000 – $500,000
- Clinical cases: 20,000+ procedures completed
- Certifications: NMPA (China), CE (Europe)
- Compared to: Globus Medical ExcelsiusGPS ($800,000+)
Toumai — Laparoscopic Surgery
MicroPort MedBot's Toumai is China's most direct answer to the da Vinci platform. It provides multi-arm laparoscopic surgery with 3D HD visualization and wristed instruments.
- Price: $400,000 – $600,000
- Status: NMPA-approved (2022); CE and FDA pathways in progress
- Compared to: Intuitive da Vinci ($1,500,000 – $2,500,000)
The price difference is dramatic — Toumai costs 60–75% less than da Vinci for comparable capabilities. As of 2026, MicroPort has installed Toumai systems in over 30 Chinese hospitals and exported initial units to Southeast Asia and Latin America.
Remebot — Neurosurgery
Remebot (Beijing) focuses on neurosurgical robots for stereotactic procedures — biopsy, electrode placement, and deep brain stimulation.
- Price: $250,000 – $400,000
- Certifications: NMPA approved; CE in progress
- Compared to: Medtronic Mazor X (spine, $800K+); ROSA Brain ($1M+)
Rehabilitation Robots
Rehabilitation robots help patients recover from stroke, spinal cord injury, and orthopedic surgery. China's Fourier Intelligence leads this segment globally by deployment count.
ExoMotus M4 — Lower-Limb Exoskeleton
The ExoMotus M4 is a powered exoskeleton for gait rehabilitation. Its adaptive control system adjusts assistance based on the patient's recovery progress, supporting both inpatient and outpatient programs.
- Price: $80,000 – $150,000
- Deployed in: 2,000+ hospitals and rehab centers across 40+ countries
- Compared to: ReWalk ($85,000), Ekso Bionics ($100,000+)
Why Robot-Assisted Rehabilitation Wins on Throughput
| Factor | Manual Therapy | Robot-Assisted |
|---|---|---|
| Sessions per therapist per day | 2–3 patients | 4–6 patients |
| Consistency | Variable | Standardized |
| Data tracking | Manual notes | Automated metrics |
| Patient engagement | Moderate | High (gamification) |
| Outcome improvement | Baseline | 20–30% faster recovery |
For a 50-bed rehab center, the throughput gain typically pays back the ExoMotus M4 within 18–24 months.
Pharmacy Automation
Siasun's pharmacy automation IV preparation system automates IV admixture and oral medication dispensing in hospital pharmacies — reducing dispensing errors and freeing pharmacist time for clinical work.
- Price: $120,000 – $250,000
- Throughput: 2,000+ prescriptions per hour
- Error reduction: 99% fewer dispensing errors vs manual
- Compared to: Omnicell ($200,000 – $500,000), Swisslog Healthcare, BD Rowa
Regulatory & Import Path (B-Class Buyer Checklist)
This is where most global procurement teams get stuck. Here's the actual path:
Verify Approval in Your Market
Medical robots must hold appropriate regulatory clearance in the destination country. The three relevant authorities:
- [NMPA](https://english.nmpa.gov.cn/) (China, formerly CFDA): All listed Chinese medical robots above are NMPA-approved
- [CE marking](https://health.ec.europa.eu/medical-devices-sector_en) (EU): TiRobot, ExoMotus M4 hold valid CE marks; Toumai and Remebot are in process
- [FDA 510(k) / De Novo](https://www.fda.gov/medical-devices/products-and-medical-procedures/medical-robotic-devices) (US): Most Chinese systems do not yet hold US clearance. MicroPort and Siasun are pursuing pre-submission tracks
Ask for the manufacturer's approval certificate ID and verify it on the relevant authority database — don't rely on marketing materials alone.
Clinical Evidence
Request peer-reviewed clinical publications. TiRobot has the strongest published evidence base among Chinese surgical robots, with PubMed-indexed studies covering thoracolumbar fusion, screw placement accuracy, and patient outcomes. Toumai clinical data is growing but still concentrated in Chinese-language journals.
Training and Service
Medical robots require extensive surgical / clinical team training. Verify the manufacturer provides:
- On-site training programs (typically 2–4 weeks per surgical team)
- Proctored cases with experienced surgeons (10–20 cases minimum)
- 24/7 technical support with regional response time SLAs
- Regular software updates (annual minimum)
- Spare parts availability commitment (typically 7–10 years post-installation)
Total Cost of Ownership (5-Year)
| Cost Component | Surgical Robot | Rehabilitation Robot | Pharmacy System |
|---|---|---|---|
| Purchase price | $350K – $600K | $80K – $150K | $120K – $250K |
| Annual maintenance | $30K – $60K | $5K – $15K | $10K – $25K |
| Consumables / year | $20K – $50K | $2K – $5K | $5K – $10K |
| Training (one-time) | $10K – $30K | $3K – $8K | $5K – $10K |
| **5-year TCO** | **$610K – $1.18M** | **$115K – $250K** | **$200K – $425K** |
Even on TCO, Chinese systems remain 40–65% cheaper than Western equivalents.
Frequently Asked Questions
Are Chinese medical robots safe and proven?
Yes, for clinically validated systems. TiRobot has 20,000+ documented procedures with published outcome data. Toumai has 1,000+ procedures across NMPA-approved Chinese hospitals. ExoMotus M4 is deployed in 2,000+ centers globally. Verify NMPA / CE certificate numbers and request peer-reviewed clinical references before procurement.
Can I import a Chinese medical robot to the US or EU?
EU: Yes, if the system holds a current CE mark (TiRobot ✓, ExoMotus M4 ✓; Toumai and Remebot in process). US: Most Chinese medical robots do not yet hold FDA clearance. MicroPort and Siasun are pursuing pre-submission tracks but commercial US deployment requires FDA clearance, which typically takes 18–36 months from filing.
What is the difference between MicroPort Toumai and Intuitive da Vinci?
Clinically, both provide multi-arm laparoscopic surgery with 3D visualization and wristed instruments. Toumai is NMPA-approved and priced at $400K–$600K. Da Vinci is FDA / CE / NMPA approved with the largest global clinical evidence base, priced at $1.5M–$2.5M. Toumai's main trade-off is geographic clearance — it cannot yet be deployed in US hospitals, while da Vinci can.
How long does it take to import a Chinese medical robot?
For CE-approved systems into the EU: 3–6 months from quote to commissioning, including shipping (typically sea freight from Shanghai or Shenzhen), customs, and on-site installation. For non-CE-approved systems, you'll need to wait for the manufacturer's approval pathway, or import under a research-use exemption depending on local law.
What warranty and service do Chinese manufacturers offer?
Standard warranties range from 12 months (basic) to 36 months (extended). Manufacturers typically provide regional service partnerships: Fourier Intelligence has direct service entities in Europe and Singapore; TINAVI partners with regional distributors. Always negotiate spare-parts availability commitment (7–10 years) into the procurement contract.
Are there subsidies for Chinese hospitals buying domestic robots?
Yes. Under China's State Council healthcare policy, public hospitals receive procurement incentives for NMPA-approved domestic medical equipment. This has accelerated TiRobot and Toumai adoption inside China, providing the clinical evidence base now driving export interest.
The Chinese Medical Robot Advantage
Chinese medical robots offer 30–75% cost savings versus Western alternatives, with clinical evidence increasingly published in international journals and growing presence in regulatory databases beyond China. For hospitals in emerging markets — Southeast Asia, Latin America, Middle East, Africa — where Western systems are unaffordable, Chinese medical robots make advanced robotic-assisted care accessible for the first time.
For developed-market hospitals managing capital constraints, NMPA + CE-approved Chinese systems offer a viable mid-tier option — particularly in rehabilitation (where price differences are smaller and CE clearance is sufficient) and in pharmacy automation (where regulatory paths are shorter).
The trajectory is clear: as more Chinese manufacturers complete FDA pathways and accumulate published clinical evidence, the cost / capability gap will become harder for Western incumbents to defend on price alone.
